Grifols Therapeutics LLC

Clinical trials sponsored by Grifols Therapeutics LLC, explained in plain language.

Now part of Grifols, S.A. GRFS NASDAQ

US subsidiary of Grifols, a global plasma-derived medicines company.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 3 Not yet finished but already full! 3 Completed 1

New shot method for Alpha-1 lung disease shows promise in early trial

Disease control Completed

This study tested a new way to give Alpha-1 protein therapy by injecting it under the skin instead of into a vein. Seventeen adults with Alpha-1 Antitrypsin Deficiency received either a low or high dose weekly for eight weeks. The main goal was to check safety and how the drug mo…

Phase 1/2 • Sponsor: Grifols Therapeutics LLC • Aim: Disease control

Last updated Jun 27, 2026 08:03 UTC

Grifols Therapeutics LLC

New shot method for Alpha-1 lung disease shows promise in early trial